CRISPR Therapeutics
CRSP
473 hedge funds and large institutions have $4.52B invested in CRISPR Therapeutics in 2021 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 194 increasing their positions, 117 reducing their positions, and 80 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 117
2.31% more ownership
Funds ownership: 50.65% → 52.96% (+2.3%)
5% less funds holding
Funds holding: 498 → 473 (-25)
25% less call options, than puts
Call options by funds: $294M | Put options by funds: $392M
26% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 80
31% less capital invested
Capital invested by funds: $6.57B → $4.52B (-$2.05B)
83% less funds holding in top 10
Funds holding in top 10: 12 → 2 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$32.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$32.1M |
| 3 |
Goldman Sachs
New York
|
+$31.6M |
| 4 |
AC
Armistice Capital
New York
|
+$27.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$85.9M |
| 2 |
Two Sigma Investments
New York
|
-$53.5M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$51.9M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$23.9M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$22M |
CRSP Hedge Fund Activity: Q3 2021 in Review
473 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2021, worth a combined $4.52B — down 31% from $6.57B a quarter earlier.
Sellers outnumbered buyers: 80 funds closed out of CRSP and 59 opened new positions — a net loss of 21 holders — while 117 trimmed existing stakes and 194 added.
The largest buyer was Bank of America, adding an estimated $32.3M. The largest seller was Two Sigma Advisers, cutting an estimated $85.9M.
- 473 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2021, down from 498 in Q2 2021.
- Funds reported $4.52B of CRISPR Therapeutics stock for Q3 2021, down 31% quarter-over-quarter.
- 59 funds opened new CRISPR Therapeutics positions in Q3 2021 and 80 closed out, a net change of -21 holders.
- The largest CRISPR Therapeutics buyer in Q3 2021 was Bank of America, an estimated $32.3M added.
- The largest CRISPR Therapeutics seller in Q3 2021 was Two Sigma Advisers, an estimated $85.9M sold.
Based on aggregated 13F filings for Q3 2021.